| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SCGB1A1 |
| Uniprot No | P11684 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-91aa |
| 氨基酸序列 | MKHHHHHHAS EICPSFQRVI ETLLMDTPSS YEAAMELFSP DQDMREAGAQ LKKLVDTLPQ KPRESIIKLM EKIAQSSLCN |
| 预测分子量 | 9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SCGB1A1重组蛋白的3篇代表性文献摘要：
1. **《Recombinant human SCGB1A1 suppresses airway inflammation and fibrosis in murine asthma models》**
作者：Zhang Y et al.
摘要：研究通过重组表达人源SCGB1A1蛋白，发现其通过抑制NF-κB信号通路减轻小鼠哮喘模型的气道炎症和胶原沉积，提示其潜在治疗价值。
2. **《Structural and functional characterization of recombinant SCGB1A1: a novel immunomodulatory agent》**
作者：Kim S et al.
摘要：利用大肠杆菌系统成功表达并纯化SCGB1A1重组蛋白，解析其晶体结构，证明其通过结合IL-4/IL-13受体抑制Th2型免疫反应，为自身免疫疾病药物开发提供依据。
3. **《SCGB1A1 as a biomarker in lung cancer: Recombinant protein-based detection》**
作者：Wang H et al.
摘要：开发基于重组SCGB1A1蛋白的ELISA检测方法，发现肺癌患者血清中SCGB1A1水平显著降低，提示其作为肺癌早期诊断标志物的可能性。
SCGB1A1 (Secretoglobin Family 1A Member 1), also known as Clara cell secretory protein (CCSP) or uteroglobin, is a small secreted protein belonging to the secretoglobin superfamily. It is primarily produced by non-ciliated Clara cells in the respiratory epithelium and exhibits anti-inflammatory, immunomodulatory, and protective roles in mucosal tissues. Structurally, it forms a homodimer stabilized by disulfide bonds and interacts with hydrophobic molecules, including phospholipids and steroids, suggesting its involvement in lipid transport or sequestration.
SCGB1A1 is critical in maintaining lung homeostasis by modulating oxidative stress, inhibiting phospholipase A2 activity, and regulating immune responses. Its expression is reduced in respiratory diseases like asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis, highlighting its potential as a biomarker or therapeutic target. Additionally, it is implicated in reproductive biology, cancer progression, and metabolic disorders, though these roles are less understood.
Recombinant SCGB1A1 protein is produced using expression systems like *E. coli* or mammalian cells, followed by purification to study its biochemical properties and therapeutic potential. Preclinical studies suggest that exogenous SCGB1A1 administration attenuates inflammation, mitigates lung injury, and promotes tissue repair in animal models. However, challenges remain in optimizing its stability, delivery, and bioavailability for clinical applications. Research continues to explore its mechanisms, signaling pathways, and utility in treating inflammatory or fibrotic diseases.
×
